IL148915A0 - Targeted drug activation - Google Patents

Targeted drug activation

Info

Publication number
IL148915A0
IL148915A0 IL14891500A IL14891500A IL148915A0 IL 148915 A0 IL148915 A0 IL 148915A0 IL 14891500 A IL14891500 A IL 14891500A IL 14891500 A IL14891500 A IL 14891500A IL 148915 A0 IL148915 A0 IL 148915A0
Authority
IL
Israel
Prior art keywords
targeted drug
drug activation
activation
targeted
drug
Prior art date
Application number
IL14891500A
Other languages
English (en)
Original Assignee
Yarmut Yehuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yarmut Yehuda filed Critical Yarmut Yehuda
Publication of IL148915A0 publication Critical patent/IL148915A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14891500A 1999-10-12 2000-10-10 Targeted drug activation IL148915A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15838399P 1999-10-12 1999-10-12
PCT/IL2000/000637 WO2001026704A2 (en) 1999-10-12 2000-10-10 Targeted drug activation

Publications (1)

Publication Number Publication Date
IL148915A0 true IL148915A0 (en) 2002-09-12

Family

ID=22567864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14891500A IL148915A0 (en) 1999-10-12 2000-10-10 Targeted drug activation

Country Status (5)

Country Link
US (1) US6576257B1 (de)
EP (1) EP1221946A4 (de)
AU (1) AU7815000A (de)
IL (1) IL148915A0 (de)
WO (1) WO2001026704A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10108798A1 (de) * 2001-02-19 2002-09-26 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur ultraschallgestützten transmembranen Medikamentenapplikation in vivo
US20080033412A1 (en) * 2006-08-01 2008-02-07 Harry Thomas Whelan System and method for convergent light therapy having controllable dosimetry
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
EP2229155A4 (de) * 2007-12-12 2010-12-29 Northern Innovations And Formulations Corp Teilchen in einer kapsel
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068283A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex VIVO modifiable particle or polymeric material medicament carrier
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
CA2798205A1 (en) * 2010-05-03 2011-11-10 University Health Network Imageable activatable agent for radiation therapy and method and system for radiation therapy
WO2013070872A1 (en) 2011-11-08 2013-05-16 The Board Of Trustees Of The University Of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
WO2015024931A1 (en) 2013-08-19 2015-02-26 Moghimi Seyed Moien Peptidic nanodelivery composition targeting two receptors
CA2935743A1 (en) 2014-01-04 2015-07-09 Vijay Agarwal Device and method for use of photodynamic therapy
EP3180085B1 (de) * 2014-08-13 2020-10-07 Convergent R.N.R Ltd Mittel und verfahren zur gezielten röntgenstrahlentherapie
EP4349401A1 (de) 2019-02-13 2024-04-10 Alpheus Medical, Inc. Nichtinvasive sonodynamische therapie
CN112618550A (zh) * 2021-01-15 2021-04-09 中国医学科学院医药生物技术研究所 抗肿瘤的尿嘧啶类化合物及其脂质组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090826A1 (de) * 1981-10-08 1983-10-12 Quentron Optics Pty. Ltd. Verbesserungen betreffend die lichtverteilung zum behandeln von tumoren
US5190761A (en) * 1986-08-05 1993-03-02 Liburdy Robert P Electromagnetic field triggered drug and chemical delivery via liposomes
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
DK0754032T3 (da) * 1994-04-08 2002-04-02 Atrix Lab Inc Flydende frigivelsessammensætninger
US6099864A (en) * 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US5957960A (en) * 1997-05-05 1999-09-28 Light Sciences Limited Partnership Internal two photon excitation device for delivery of PDT to diffuse abnormal cells

Also Published As

Publication number Publication date
EP1221946A4 (de) 2004-12-22
US6576257B1 (en) 2003-06-10
WO2001026704A2 (en) 2001-04-19
AU7815000A (en) 2001-04-23
WO2001026704A3 (en) 2001-10-18
EP1221946A2 (de) 2002-07-17

Similar Documents

Publication Publication Date Title
HK1200316A1 (en) Therapeutic microfoams
IL148915A0 (en) Targeted drug activation
EG23858A (en) Drug combination
GB9930079D0 (en) Medicaments
GB9930071D0 (en) Medicaments
GB9911802D0 (en) Therapeutic combination
GB9911803D0 (en) Therapeutic combination
GB9911804D0 (en) Therapeutic combination
GB9928607D0 (en) Syringes
ZA200110046B (en) Therapeutic agents.
GB9924990D0 (en) Medicaments
GB9930083D0 (en) Medicaments
GB9930160D0 (en) Drug delivery
GB9929040D0 (en) Medicaments
GB9930082D0 (en) Medicaments
GB9907234D0 (en) Drug assay
LT2001034A (en) Antiarrythmic drug
GB9906124D0 (en) Therapeutic agent
GB0016585D0 (en) Syringe
GB9921064D0 (en) Drug combination
GB9929039D0 (en) Medicaments
GB9904935D0 (en) Medicaments
GB9902593D0 (en) Drug combinations
GB9911499D0 (en) Medicament
GB9929405D0 (en) Medicament

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees